GILEAD SCIENCES, INC. Effective Income Tax Rate Reconciliation, Tax Credit, Percent
GILEAD SCIENCES, INC. (GILD) reported Effective Income Tax Rate Reconciliation, Tax Credit, Percent of 31.60% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-28.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits · last filed 2025-02-28
- GILEAD SCIENCES, INC. effective income tax rate reconciliation, tax credit, percent for fiscal 2024 was 31.60%, a 634.88% increase from fiscal 2023.
- GILEAD SCIENCES, INC. effective income tax rate reconciliation, tax credit, percent for fiscal 2023 was 4.30%, a 59.26% increase from fiscal 2022.
- GILEAD SCIENCES, INC. effective income tax rate reconciliation, tax credit, percent for fiscal 2022 was 2.70%, a 68.75% increase from fiscal 2021.
- GILEAD SCIENCES, INC. effective income tax rate reconciliation, tax credit, percent for fiscal 2021 was 1.60%, a 76.81% decline from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Percent 12 month |
|---|---|
| 2024-12-31 | 31.60% 10-K · filed 2025-02-28 |
| 2023-12-31 | 4.30% 10-K · filed 2025-02-28 |
| 2022-12-31 | 2.70% 10-K · filed 2025-02-28 |
| 2021-12-31 | 1.60% 10-K · filed 2024-02-23 |
| 2020-12-31 | 6.90% 10-K · filed 2023-02-22 |
| 2019-12-31 | 1.90% 10-K · filed 2022-02-23 |
| 2018-12-31 | 1.10% 10-K · filed 2021-02-25 |
| 2017-12-31 | 0.60% 10-K · filed 2020-02-25 |
| 2016-12-31 | 0.70% 10-K · filed 2019-02-26 |
| 2015-12-31 | 0.70% 10-K · filed 2018-02-27 |
| 2014-12-31 | 0.90% 10-K · filed 2017-02-27 |
| 2013-12-31 | 3.00% 10-K · filed 2016-02-24 |
| 2012-12-31 | 0.40% 10-K · filed 2015-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |